Team Leader Medicinal Chemistry
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit (CRUK CTU) within Division of Cancer Therapeutics is ranked among the world’s best academic cancer drug discovery and development groups. Led by Professor Raj Chopra, CTU is a multidisciplinary 'bench to bedside' centre, comprising around 170 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. Its 12 research teams cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials.
CRUK CTU now seeks to appoint a Team Leader in Medicinal Chemistry who will lead an independent chemistry research team that will contribute to the overall strategy and goals of the CTU. Reporting to the Unit Director Professor Raj Chopra and the Head of Chemistry Professor Ian Collins, the successful appointee will lead the application of medicinal and synthetic chemistry approaches to progress innovative small molecule anticancer compounds to proof-of-concept clinical trials. Commitment to translational and drug discovery research is critical to this position.
The successful candidate will be an established medicinal chemist with experience in drug discovery, and demonstrable ability to develop a research programme aligned with the overall research strategy of CTU. With the opportunity to appoint a number of core-funded scientists to their team, the post holder will have a reputation for high quality research and intellectual leadership, and the ability to personally lead and mentor a laboratory research team. Experience of drug discovery and translational research is essential, and experience of working within a pharmaceutical or biotechnology company is highly desirable. Enthusiasm for working in a focussed and collaborative interdisciplinary environment is essential. The successful candidate will have the drive and ability to publish high quality research in leading medicinal chemistry and/or chemical biology journals, and to pursue funding opportunities for new areas of research.
Further information, including details of how to apply, can be downloaded at https://candidates.perrettlaver.com/vacancies/ quoting reference 3767.
Applications should consist of a letter of motivation and complete curriculum vitae including a publication and patent application list.
The closing date for applications is Friday 28th June. Applications will be considered by the selection committee in early July and shortlisted candidates will subsequently be invited for campus visits and first stage interviews with representatives from the Division of Cancer Therapeutics. Final interviews are expected to take place in September 2019.
The ICR particularly welcomes female applicants and those from an ethnic minority, as they are underrepresented within The Institute at these levels.
We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff. We particularly welcome applications from women and people from ethnic minorities, as they are under-represented at the ICR at this level.